Possible uses of fecal bacteriotherapy
Authors:
Stebel Roman; Husa Petr
Authors‘ workplace:
Klinika infekčních chorob Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno
Published in:
Geriatrie a Gerontologie 2023, 12, č. 2: 83-87
Category:
Review Article
Overview
The problematic of intestinal dysbiosis is currently an object of intensive research, alteration of microbiota is related to pathogenesis of a whole array of disease states. A certain prototype of illness at which disruption of natural balance of intestinal microbial ecosystem plays a key role is recurrent Clostridium difficile colitis. A very hopeful method having the potential to therapeutically intervene exactly at the level of altered intestinal microbiota is fecal bacteriotherapy. It is already globally established method with aim to achieve the restoration of natural microbial homeostasis in the intestine using stool of healthy donor which is transplanted into the intestines of a patient. By restoring the colonization resistance of large intestine, the transplantation of intestinal microbiota can break an imaginary vicious cycle of repeated attacks of Clostridium difficile colitis. Within secondary prophylaxis of recurrent Clostridium difficile colitis, fecal bacteriotherapy is a very effective, safe, and by patients well-tolerated method. We can see its future in both improvement of the fecal transplant administration method (including enteric capsules) and more targeted manipulation with intestinal microbiota which will lead to extension of indications by an array of other illnesses.
Keywords:
Clostridioides difficile – intestinal dysbiosis – pseudomembranous enterocolitis – faecal microbiota transplantation
Sources
1. Rao K, Young VB. Fecal microbiota transplantation for the management of Clostridium difficile infection. Infect Dis Clin North Am 2015; 29(1): 109–122.
2. Ooijevaar RE, Terveer EM, Verspaget HW, et al. Clinical application and potential of fecal microbiota transplantation. Annu Rev Med 2019; 70(1): 335–351.
3. Kohout P, Vejmelka J. Fekální bakterioterapie v léčbě recidivující klostridiové enterokolitidy. Postgraduální Medicína 2014; 16(7): 729–734.
4. Gens KD, Elshaboury RH, Holt JS. Fecal microbiota transplantation and emerging treatments for Clostridium difficile infection. J Pharm Pract 2013; 26(5): 498–505.
5. Wilson BC, Vatanen T, Cutfield WS, et al. The super-donor phenomenon in fecal microbiota transplantation. Front Cell Infect Microbiol 2019; 9: 2.
6. Johnsen PH, Hilpüsch F, Cavanagh JP, et al. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel- group, single-centre trial. Lancet Gastroenterol Hepatol 2018; 3(1): 17–24.
7. Bajaj JS, Kassam Z, Fagan A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 2017; 66(6): 1727–1738.
8. Mullish BH, Mcdonald JAK, Thursz MR, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology 2017; 66(4): 1354–1355.
9. Marotz CA, Zarrinpar A. Treating obesity and metabolic syndrome with fecal microbiota transplantation. Yale J Biol Med 2016; 89(3): 383–388.
10. Kang DW, Adams JB, Gregory AC, et al. Microbiota transfer therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 2017; 5(1).
11. Yang Y, Tian J, Yang B. Targeting gut microbiome: A novel and potential therapy for autism. Life Sci 2018; 194: 111–119.
12. Ooijevaar RE, van Beurden YH, Terveer EM, et al. Update of treatment algorithms for Clostridium difficile infection. Clin Microbiol Infect 2018; 24(5): 452–462.
13. Wang JW, Kuo CH, Kuo FC, et al. Fecal microbiota transplantation: Review and update. J Formos Med Assoc 2019; 118, 23–31.
14. Wang T, Kraft CS, Woodworth MH, et al. Fecal microbiota transplant for refractory Clostridium difficile infection interrupts 25-year history of recurrent urinary tract infections. Open Forum Infect Dis 2018; 5(2).
15. Moutinho BD, Baima JP, Rigo FF, et al. Fecal microbiota transplantation in refractory ulcerative colitis – a case report. J Int Med Res 2019; 47(2): 1072–1079.
16. Cotter PD, Ross RP, Hill C. Bacteriocins – a viable alternative to antibiotics? Nat Rev Microbiol 2013; 11(2): 95–105.
17. Ofir G, Sorek R. Contemporary phage biology: from classic models to new insights. Cell. 2018; 172(6): 1260–1270.
18. Khoruts A, Sadowsky MJ. Understanding the mechanisms of faecal microbiota transplantation. Nat Rev Gastroenterol Hepatol 2016; 13(9): 508–516.
19. Morrison DJ, Preston T. Formation of short chain fatty acids by the gut microbiota and their impact on human metabolism. Gut Microbes 2016; 7(3): 189–200.
20. Corrêa-Oliveira R, Fachi JL, Vieira A, et al. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immuno 2016; 5(4): e73.
21. Mills JP, Rao K, Young VB. Probiotics for prevention of Clostridium difficile infection: Curr Opin Gastroenterol 2018; 34(1): 3–10.
22. Winston JA, Theriot CM. Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract. Anaerobe 2016; 41: 44–50.
23. Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: prevention, diagnosis, and treatment of Clostridioides difficile infections. Am J Gastroenterol 2021; 116(6): 1124–1147.
24. van Prehn J, Reigadas E, Vogelzang EH, et al. European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults. Clin Microbiol Infect 2021; 27: S1–S21.
25. Beneš J, Stebel R, Musil V, et al. Aktualizovaný doporučený postup pro léčbu nemocných s kolitidou vyvolanou Clostridioides difficile. Klin Mikrobiol Inf Lék 2022; 28(3): 77–94.
26. Polívková S, Vojtilová L, Husa P, et al. Doporučený postup fekální bakterioterapie pro léčbu rekurentní klostridiové kolitidy. Klin Mikrobiol Inf Lék 2018; 24(2): 57–64.
27. Polák P, Freibergerová M, Juránková J, et al. První zkušenosti s fekální bakterioterapií v léčbě relabující pseudomembranózní kolitidy způsobené Clostridium difficile. Klin Mikrobiol Inf Lék 2011; 17(6): 214–217.
28. Stebel R, Vojtilová L, Svačinka R, et al. Faecal microbiota transplantation in the treatment of Clostridioides difficile infection. Hum Microbiome J 2020; 16: 100070.
29. Stebel R, Svačinka R, Vojtilová L, et al. Fekální bakterioterapie v léčbě klostridiové kolitidy. Epidemiol Mikrobiol Imunol 2018; 67(3): 104–109.
30. Polák P, Freibergerová M, Husa P, et al. Fekální bakterioterapie v léčbě rekurentní kolitidy způsobené Clostridium difficile na Klinice infekčních chorob Fakultní nemocnice Brno v letech 2010–2014 – prospektivní studie. Epidemiol Mikrobiol Imunol 2015; 64(4).
31. Tariq R, Pardi DS, Bartlett MG, et al. Low cure rates in controlled trials of fecal microbiota transplantation for recurrent Clostridium difficile infection: a systematic review and meta-analysis. Clin Infect Dis 2019; 68(8): 1351–1358.
32. Hui W, Li T, Liu W, et al. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis. PLOS ONE 2019; 14(1): e0210016.
33. Li YT, Cai HF, Wang ZH, et al. Systematic review with meta- -analysis: long-term outcomes of faecal microbiota transplantation for Clostridium difficile infection. Aliment Pharmacol Ther 2016; 43(4): 445–457.
34. Allegretti JR, Fischer M, Sagi SV, et al. Fecal microbiota transplantation capsules with targeted colonic versus gastric delivery in recurrent Clostridium difficile infection: a comparative cohort analysis of high and lose dose. Dig Dis Sci 2019; 64(6): 1672– 1678.
35. Terveer EM, van Beurden YH, Goorhuis A, et al. How to: Establish and run a stool bank. Clin Microbiol Infect 2017; 23(12): 924–930.
36. Cammarota G, Ianiro G, Tilg H, et al. European consensus conference on faecal microbiota transplantation in clinical practice. Gut 2017; 66(4): 569– 580.
37. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 2013; 368(5): 407–415.
Labels
Geriatrics General practitioner for adults Orthopaedic prostheticsArticle was published in
Geriatrics and Gerontology
2023 Issue 2
Most read in this issue
- Presbyphagia versus dysphagia – the role of the speech therapist in the management of swallowing disorders
- Frailty – prevalence of acutely hospitalized seniors from 1995 to 2022
- Mental and physical condition of patients in postacute hospital care – analysis of the results of a Czech literature review
- Results of surgical treatment of proximal femur fractures in patients operated at the Traumatology Clinic of the University Hospital Olomouc in the years 2017–2021